Advertisement

Pharmaceutical Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X
Analysis

Bias remorse: are cancer drug trials clear enough on outcomes?

New analysis published in the British Medical Journal has found that almost half of pivotal trials forming the basis of EMA approvals of new cancer drugs were at high risk of bias based on their design, conduct or analysis. What exactly are the problems with cancer trial design and administration, and what needs to change? Study co-author Dr Huseyin Naci lends his insight.

Close
Close
Close

Go Top